LAG-3 and PD-1 Inhibitor Combination for Synergistic T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments targeting the PD-1 pathway, such as pembrolizumab and nivolumab, are limited in their effectiveness for a wider range of cancer patients and often come with significant side effects, necessitating the development of more potent and less toxic therapies.
Innovation Solution
A combined preparation comprising a LAG-3 protein or its derivative that binds to MHC class II molecules and a PD-1 pathway inhibitor, administered together to synergistically activate T cells, particularly CD8+ T cells, enhancing anti-tumor immune responses with potentially reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PD-1 pathway inhibitors (pembrolizumab, nivolumab) are used as monotherapy, then T cell activation is enhanced, but treatment effectiveness is limited and side effects are significant
Solution Approach 1:
The patent combines LAG-3 protein (or derivative) and PD-1 pathway inhibitor into a single combined preparation administered together, creating a synergistic effect that enhances T cell activation more effectively than either agent alone while reducing treatment-related side effects
2Adaptability or versatility
If PD-1 pathway inhibitors are used alone, then some anti-tumor response is achieved, but the range of responsive cancer patients is limited
Solution Approach 1:
By combining two different immune checkpoint targets (LAG-3 and PD-1), the preparation addresses multiple immune evasion mechanisms used by tumors, thereby expanding the range of cancer types and patients who respond to treatment while maintaining or enhancing effectiveness
3Power
If single-agent PD-1 inhibition is used, then treatment simplicity is maintained, but therapeutic potency is insufficient
Solution Approach 1:
The patent merges two active ingredients (LAG-3 protein and PD-1 inhibitor) into a single combined preparation that is administered as one treatment, thereby achieving synergistic therapeutic potency while maintaining treatment simplicity and avoiding the need for separate administration of multiple agents
Data Source
AI summary
Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8+ T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.